CTRI/2021/12/038530尚未招募未知
Three Capsules as Single dose Fasting In Vivo Comparative Bioavailability Study of Maxicuma 500 mg Capsule (India Glycols Limited, India) with Three Capsules as Single dose of 95% Curcuminoid 500 mg Capsules (India Glycols Limited, India) in healthy adult, human subjects - Bioequivalence Study
India Glycols Limited0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •1. Healthy volunteers within the age range of 18 to 45 years (both inclusive).
- •2. Presently non-tobacco users (smokers and chewers).
- •3. Willingness to provide written informed consent to participate in the study.
- •4. Body-mass index (BMI) between 18.50 kg/m2 and 29.99 kg/m2 (both inclusive) with body weight not less than 50 kg (for males) and with body weight not less than 45 kg (for females).
- •5. Absence of significant disease or clinically significant laboratory values or laboratory evaluation, medical history or physical examination during the screening.
- •6. Have a normal 12-lead ECG or one with abnormality considered to be clinically insignificant.
- •7. Have a normal chest X-ray PA view or one with abnormality considered to be clinically insignificant.
- •8. Willing to take turmeric free food for the entire study duration.
- •9. Comprehension of the nature and purpose of the study and compliance with the requirement of the distributed ICF.
- •10. Volunteer is regularly menstruating / Volunteer is in postmenopausal phase for at least 1 year / is surgically sterile (for females).
- •11. Volunteer of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s) such as condoms, foams, jellies, diaphragm, and intrauterine device (IUD) or abstinence etc. except hormonal contraceptives (for females).
排除标准
- •1. Personal history of allergy or hypersensitivity to Curcumin or to any components of the formulation or allied drugs or excipients.
- •2. Any major illness in the past 90 days or any clinically significant ongoing chronic medical illness e.g. Congestive Cardiac Failure, Hepatitis, Hypotensive episodes,
- •Hyperglycemia etc.
- •3. Presence of any clinically significant abnormal laboratory values during screening e.g. significant abnormality of liver function test, renal function test etc.
- •4. Severe cardiac, renal or liver impairment, gastro-intestinal disease or other conditions, any other organ or system impairment.
- •5. History of seizures, epilepsy or any kind of Neurological disorders.
- •6. History of hypercalcemia or vitamin D toxicity.
- •7. Past history of Anaphylaxis or angioedema.
- •8. Presence of disease markers of HIV or Hepatitis B or Hepatitis C virus.
- •9. History of chronic consumption of any kind of alcoholic beverages for more than 2 years or having consumed alcohol within 48 hours prior to check-in.
- •10. Consumption of products containing xanthine derivatives (chocolates, tea, coffee or cola drinks) or tobacco products within 48 hours prior to check-in.
- •11. Consumption of grapefruit or grapefruit containing products or any cruciferous vegetables (eg. broccoli, brussels sprouts, etc.) or char-broiled meat prior 7 days of investigational product administration.
- •12. Use of any recreational drug or a history of drug addiction.
- •13. Participation in any clinical trial within the past 90 days.
- •14. History of difficulty with donating blood or difficulty in accessibility of veins in left or right arm.
- •15. Donation of blood (one unit or 350 mL) within 90 days prior to receiving the first dose of study medication.
- •16. Consumption of any other prescription drug or over the counter (OTC) drugs (including vitamins and medicinal products from natural origin) within two weeks prior to receiving the first dose of study medication or repeated use of drugs within the last four weeks and throughout subjectâ??s participation in the study.
- •17. An unusual diet for whatever reason e.g. low sodium diet, for two weeks prior to receiving any medication and throughout subjectâ??s participation in the study.
- •18. Recent history of dehydration from diarrhoea, vomiting or any other reason within a period of 48 hours prior to the study.
- •19. Use of oral contraceptive in last 90 days (for females).
- •20. Pregnant / lactating volunteers (for females).
研究者
相似试验
尚未招募
1 期
A single dose study under fasting condition to access the Bioequivalence of Etoricoxib 120 mg tablets (Test formulation), manufactured by Interthai Pharmaceutical Manufacturing Limited with a reference formulation Arcoxia® - MSD, in 24 healthy volunteersBioequivalence study in healthy volunteersBioequivalence,EtoricoxibTCTR20170201002Bio-innova and Synchron.Co.,Ltd24
尚未招募
1 期
A Single-Dose study under fasting condition to assess the Bioequivalence of Etoricoxib 120 mg tablets (Test formulation), provided by DKSH (Thailand) Limited with a reference formulation Arcoxia® 120 mg tablets, in 24 healthy volunteersBioequivalence studyBioequivalenceEtoricoxibTCTR20181008002Bio-innova and Synchron.Co.,Ltd24
尚未招募
1 期
A Single-Dose study under fasting condition to assess the Bioequivalence of Febuxostat 80 mg tablets (Test formulation), provided by DKSH (Thailand) Limited with a reference formulation Feburic(R) 80 mg tablets, in 32 healthy volunteersBioequivalence studyFebuxostatTCTR20200916003Bio-innova and Synchron.Co.,Ltd32
已完成
不适用
A Study of Viagra and XCalibur in Healthy Volunteers.ACTRN12616001712493iX Biopharma Ltd.48
已完成
1 期
Bioequivalence Study Between "DA-5209 Tab" and "Lixiana Tab"HealthyNCT04671316Dong-A ST Co., Ltd.121